Summit reports two-year survival data for Western patients, though context lacking

July 22, 2026 07:37 AM EDT R&D Sum­mit re­ports two-year sur­vival da­ta for West­ern pa­tients, though con­text lack­ing Max Gelman Senior Editor Sum­mit Ther­a­peu­tics un­veiled ad­di­tion­al fol­low-up da­ta on its ex­per­i­men­tal can­cer drug ivonescimab, and how its ben­e­fit com­pares be­tween Asian and West­ern pa­tients. But key con­text … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER